Details of the Drug

General Information of Drug (ID: DMTTW9V)

Drug Name

NBI-921352

Synonyms

Zandatrigine; XEN901; NBI-921352; XEN-901; SV2WPA4R4J; UNII-SV2WPA4R4J; 2154406-04-7; Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3S)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-N-4-thiazolyl-; Benzenesulfonamide, 2-fluoro-5-methyl-4-[methyl[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]-N-4-thiazolyl-; zandatrigine [INN]; CHEMBL4650313; SCHEMBL19613237; GTPL11734; BDBM470680; (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide formate; NBI921352; US10815229, Example 101; AKOS040757364; MS-28458; HY-147423; CS-0564178; F84519; 4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide; 4-{[(3S)-1-benzylpyrrolidin-3-yl](methyl)amino}-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Epileptic encephalopathy	8A62	Phase 2	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C22H25FN4O2S2
Canonical SMILES: CC1=CC(=C(C=C1N(C)C2CCN(C2)CC3=CC=CC=C3)F)S(=O)(=O)NC4=CSC=N4
InChI: InChI=1S/C22H25FN4O2S2/c1-16-10-21(31(28,29)25-22-14-30-15-24-22)19(23)11-20(16)26(2)18-8-9-27(13-18)12-17-6-4-3-5-7-17/h3-7,10-11,14-15,18,25H,8-9,12-13H2,1-2H3/t18-/m0/s1
InChIKey: UCSHINHOAVARGQ-SFHVURJKSA-N

Cross-matching ID

PubChem CID: 132141687
ChEBI ID: CHEMBL4650313
TTD ID: DMT4U6

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.6 (SCN8A)	TT54ERL	SCN8A_HUMAN	Inhibitor	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05226780) A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Neurocrine Biosciences